We are analyzing https://link.springer.com/article/10.1007/s00520-005-0913-5.

Title:
Bisphosphonates for malignancy-related bone disease: current status, future developments | Supportive Care in Cancer
Description:
This review relates to the efficacy and safety of bisphosphonates in metastatic bone disease. It discusses practical recommendations and possible future indications for bisphosphonate therapy. The current aims of bisphosphonates for metastatic bone disease are to prevent skeletal-related events (SREs), reduce bone pain and improve quality of life. Phase III clinical trials of clodronate and pamidronate have established their efficacy against bone complications in patients with breast cancer and multiple myeloma, while randomized trials have shown SRE reductions with zoledronic acid in patients with breast cancer and multiple myeloma, prostate cancer, and lung and other solid tumors. These bisphosphonates also have some effect on metastatic bone pain. Ibandronate is a new aminobisphosphonate, available in more than 40 countries outside of the US as intravenous and oral formulations for the prevention of skeletal events in patients with breast cancer and bone metastases. Phase III studies have shown that both intravenously and orally administered ibandronate have efficacy for the prevention of skeletal events and for the reduction of metastatic bone pain. In addition to efficacy, the long-term tolerability of bisphosphonates in metastatic bone disease influences drug selection. Besides their use in patients with established bone metastases, recent and ongoing research suggests that bisphosphonates also have clinical benefit in the adjuvant setting, and for the treatment of cancer-treatment-induced bone loss. Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, google, scholar, bone, pubmed, article, cas, breast, patients, metastases, oncol, bisphosphonates, metastatic, clin, acid, body, zoledronic, skeletal, treatment, disease, trial, pain, ibandronate, clodronate, pamidronate, randomized, oral, abstract, complications, suppl, intravenous, therapy, prostate, adjuvant, doubleblind, placebocontrolled, phase, longterm, efficacy, safety, clinical, prevention, study, proc, soc, support, care, bisphosphonate, iii, multiple,

Topics {✒️}

month download article/chapter opioid-resistant bone pain cancer-treatment-induced bone loss jean-jacques body shortened infusion time article supportive care malignancy-related bone disease breast-cancer induced osteolysis chemotherapy-induced ovarian failure double-blind controlled trial placebo-controlled multicenter trial prevent skeletal-related events full article pdf placebo-controlled randomized trial biochemical dose-response study double-blind randomised trial adjuvant pamidronate therapy placebo-controlled study privacy choices/manage cookies zoledronic acid compared placebo-controlled studies tumor-induced osteolysis open-label study ongoing research suggests metastatic bone disease rosen ls placebo-controlled trial article body oral ibandronate compared prevent bone loss bone mineral density metastatic breast carcinoma operable breast cancer phase iii studies metastatic bone pain related subjects bisphosphonate therapy zoledronic acid delays skeletal-related events intravenous ibandronate reduces metastatic breast cancer oral ibandronate reduces long-term impact tumor bone diseases bone health issues advanced breast cancer renal cell carcinoma main adverse events support care cancer metastatic urologic cancer

Questions {❓}

Body J, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Bisphosphonates for malignancy-related bone disease: current status, future developments
         description:This review relates to the efficacy and safety of bisphosphonates in metastatic bone disease. It discusses practical recommendations and possible future indications for bisphosphonate therapy. The current aims of bisphosphonates for metastatic bone disease are to prevent skeletal-related events (SREs), reduce bone pain and improve quality of life. Phase III clinical trials of clodronate and pamidronate have established their efficacy against bone complications in patients with breast cancer and multiple myeloma, while randomized trials have shown SRE reductions with zoledronic acid in patients with breast cancer and multiple myeloma, prostate cancer, and lung and other solid tumors. These bisphosphonates also have some effect on metastatic bone pain. Ibandronate is a new aminobisphosphonate, available in more than 40 countries outside of the US as intravenous and oral formulations for the prevention of skeletal events in patients with breast cancer and bone metastases. Phase III studies have shown that both intravenously and orally administered ibandronate have efficacy for the prevention of skeletal events and for the reduction of metastatic bone pain. In addition to efficacy, the long-term tolerability of bisphosphonates in metastatic bone disease influences drug selection. Besides their use in patients with established bone metastases, recent and ongoing research suggests that bisphosphonates also have clinical benefit in the adjuvant setting, and for the treatment of cancer-treatment-induced bone loss. Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future.
         datePublished:2006-02-01T00:00:00Z
         dateModified:2006-02-01T00:00:00Z
         pageStart:408
         pageEnd:418
         sameAs:https://doi.org/10.1007/s00520-005-0913-5
         keywords:
            Bisphosphonates
            Ibandronate
            Zoledronic acid
            Bone metastases
            Adjuvant
            Oncology
            Nursing
            Nursing Research
            Pain Medicine
            Rehabilitation Medicine
         image:
         isPartOf:
            name:Supportive Care in Cancer
            issn:
               1433-7339
               0941-4355
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jean-Jacques Body
               affiliation:
                     name:Université Libre de Bruxelles
                     address:
                        name:Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Bisphosphonates for malignancy-related bone disease: current status, future developments
      description:This review relates to the efficacy and safety of bisphosphonates in metastatic bone disease. It discusses practical recommendations and possible future indications for bisphosphonate therapy. The current aims of bisphosphonates for metastatic bone disease are to prevent skeletal-related events (SREs), reduce bone pain and improve quality of life. Phase III clinical trials of clodronate and pamidronate have established their efficacy against bone complications in patients with breast cancer and multiple myeloma, while randomized trials have shown SRE reductions with zoledronic acid in patients with breast cancer and multiple myeloma, prostate cancer, and lung and other solid tumors. These bisphosphonates also have some effect on metastatic bone pain. Ibandronate is a new aminobisphosphonate, available in more than 40 countries outside of the US as intravenous and oral formulations for the prevention of skeletal events in patients with breast cancer and bone metastases. Phase III studies have shown that both intravenously and orally administered ibandronate have efficacy for the prevention of skeletal events and for the reduction of metastatic bone pain. In addition to efficacy, the long-term tolerability of bisphosphonates in metastatic bone disease influences drug selection. Besides their use in patients with established bone metastases, recent and ongoing research suggests that bisphosphonates also have clinical benefit in the adjuvant setting, and for the treatment of cancer-treatment-induced bone loss. Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future.
      datePublished:2006-02-01T00:00:00Z
      dateModified:2006-02-01T00:00:00Z
      pageStart:408
      pageEnd:418
      sameAs:https://doi.org/10.1007/s00520-005-0913-5
      keywords:
         Bisphosphonates
         Ibandronate
         Zoledronic acid
         Bone metastases
         Adjuvant
         Oncology
         Nursing
         Nursing Research
         Pain Medicine
         Rehabilitation Medicine
      image:
      isPartOf:
         name:Supportive Care in Cancer
         issn:
            1433-7339
            0941-4355
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jean-Jacques Body
            affiliation:
                  name:Université Libre de Bruxelles
                  address:
                     name:Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Supportive Care in Cancer
      issn:
         1433-7339
         0941-4355
      volumeNumber:14
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Université Libre de Bruxelles
      address:
         name:Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jean-Jacques Body
      affiliation:
            name:Université Libre de Bruxelles
            address:
               name:Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(224)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.3s.

LINK . SPRINGER . COM {}